Opinion|Videos|January 2, 2025
Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, highlighting its safety profile and 100% minimal residual disease (MRD) negativity after cycle 3, and explores how using bispecific antibodies like teclistamab earlier in treatment could influence future options for relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Bispecific antibodies have had a significant impact on the treatment landscape for R/R multiple myeloma. Data presented at ASH is evaluating the use of bispecifics earlier in treatment. Briefly describe the data presented on MajesTEC-5, which evaluates teclistamab in combination with standard therapy in the frontline setting.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Primary end point: safety
- Secondary end point: MRD negativity, 100% after cycle 3
- How might using teclistamab in earlier lines of therapy influence treatment options in the relapsed setting?
Advertisement
Related to this article
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5